Altavo GmbH secured €3 million in a Series A2 funding round to enhance AI-based voice rehabilitation for individuals with speech loss.
Target Company Overview
Altavo GmbH is a medical technology startup specializing in AI-based voice rehabilitation, which successfully closed a €3 million Series A2 funding round on January 12, 2026. The investment is led by a European consortium including Novalis Biotech and Beteiligungsmanagement Thüringen, with additional participation from TGFS Technologiegründerfonds Sachsen, High-Tech Gründerfonds (HTGF), TUDAG TU Dresden AG, Ostwerk GmbH, and private investors.
Altavo's innovative technology aims to provide a natural-sounding voice to individuals who have lost their voice due to circumstances such as laryngectomy or artificial ventilation. Developed in collaboration with researchers from the Technical University of Dresden, the “Silent Speech” technology relies on non-invasive radar sensors and advanced AI algorithms to recreate a person’s voice.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Germany
The medical technology sector in Germany ranks among the most advanced globally, characterized by a strong emphasis on research and development. The industry benefits from a well-established framework, combining
Similar Deals
Novalis Biotech
invested in
Altavo GmbH
in 2026
in a Series A deal
Disclosed details
Transaction Size: $3M